Adverse effects · People with American cutaneous and mucocutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis
Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA)… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo + IVMA (moderate certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis
Thermotherapy one session (at 50 ºC for 30 seconds) leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg Sb5/kg/day (high certainty).
1 finding from 1 review
Adverse effects · People with American cutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
Recurrence · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in recurrence compared with placebo (3 tablets/4 times a day (low certainty).
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) probably leads to higher complete cure, at least 3 months after the end of treatment compared with placebo (same regimen) (moderate certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).
1 finding from 1 review
Recurrence · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) showed no clear difference in recurrence compared with placebo (same regimen) (low certainty).
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg/kg 20 days) (low certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Percentage of participants reaching PASI 75 · people with paediatric psoriasis
Etanercept leads to higher PASI 75 Participants achieving a 75% improvement in the Psoriasis… compared with placebo (high certainty).
1 finding from 1 review
PASI 50 · people with paediatric psoriasis
Etanercept leads to higher PASI 50 Participants achieving a 50% improvement in the Psoriasis… compared with placebo (high certainty).
1 finding from 1 review
PASI 90 · people with paediatric psoriasis
Etanercept leads to higher PASI 90 Participants achieving a 90% improvement in the Psoriasis… compared with placebo (high certainty).
1 finding from 1 review
PGA Participants achieving a PGA of 'clear' or 'almost clear' · people with paediatric psoriasis
Etanercept leads to higher PGA Participants achieving a PGA of 'clear' or 'almost clear' compared with placebo (high certainty).
1 finding from 1 review